Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 18/20 | 0.70 |
| ▸ | EDNRB | P24530 | 11/20 | 0.66 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.55 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | DHPS | P49366 | 1/20 | 0.55 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.55 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31559142 | 1.00 | EDNRA (0.70) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL31559141 | 1.00 | EDNRA (0.70) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Potassium SCHEMBL31559138 | 0.99 | EDNRA (0.69) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL629196 | 0.99 | EDNRA (0.69) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Dimethyl Sulfoxide SCHEMBL627619 | 0.96 | EDNRA (0.66) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7331882 | 0.90 | EDNRA (0.60) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7297111 | 0.89 | EDNRA (0.57) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7306773 | 0.89 | EDNRA (0.57) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7295442 | 0.87 | EDNRA (0.55) | EDNRAEDNRB | |
| SCHEMBL7296967 | 0.87 | EDNRA (0.57) | EDNRAEDNRBABCC3ABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120136015-A1 | PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN) | SANDOZ AG (CH) | 2012-05-31 | — | — | US | claimed |
| EP-2419421-A1 | PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN) | Sandoz AG (CH) | 2012-02-22 | — | — | EP | claimed |
| WO-2010118992-A1 | PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN) | SANDOZ AG (CH) | 2010-10-21 | — | — | WO | claimed |
| CN-114415524-B | Heuristic collaborative multi-aircraft trajectory cross analysis and conflict resolution method | 中国人民解放军96901部队 | 2022-06-21 | — | — | CN | disclosed |
| CN-114415524-A | Heuristic collaborative multi-aircraft trajectory cross analysis and conflict resolution method | 中国人民解放军96901部队 | 2022-04-29 | — | — | CN | disclosed |
| US-20120136015-A1 | PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN) | SANDOZ AG (CH) | 2012-05-31 | — | — | US | disclosed |
| EP-2419421-A1 | PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN) | Sandoz AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| EP-2294056-A1 | BOSENTAN SALTS | Synthon B.V. (NL) | 2011-03-16 | — | — | EP | disclosed |
| WO-2010118992-A1 | PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN) | SANDOZ AG (CH) | 2010-10-21 | — | — | WO | disclosed |
| US-20100256371-A1 | PROCESSES FOR THE PREPARATION OF BOSENTAN AND ITS INTERMEDIATES THEREOF | GLENMARK (IN) | 2010-10-07 | — | — | US | disclosed |
| US-20090291974-A1 | BOSENTAN SALTS | SYNTHON BV (NL) | 2009-11-26 | — | — | US | disclosed |
| US-20030087920-A1 | Butyne diol derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2003-05-08 | — | — | US | disclosed |
| EP-1244637-A1 | BUTYNE DIOL DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001081335-A1 | PYRIMIDINE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2001-11-01 | — | — | WO | disclosed |
| EP-1137642-A1 | BIS-SULFONAMIDES | Actelion Pharmaceuticals Ltd. (CH) | 2001-10-04 | — | — | EP | disclosed |
| WO-2001046156-A1 | BUTYNE DIOL DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001017976-A1 | BIS-SULFONAMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2001-03-15 | — | — | WO | disclosed |
| EP-0526708-B1 | Sulfonamide, preparation and use thereof as medicine and intermediate | HOFFMANN LA ROCHE (CH) | 2000-10-18 | — | — | EP | disclosed |
| US-5292740-A | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 1994-03-08 | — | — | US | disclosed |
| EP-0526708-A1 | Sulfonamide, preparation and use thereof as medicine and intermediate | F. HOFFMANN-LA ROCHE AG (CH) | 1993-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291974-A1 | BOSENTAN SALTS | PDE9A, PDE7A, PDE3A | EDNRA 21/4885EDNRB 19/4885ABCC3 4013/4885 |
| US-20100256371-A1 | PROCESSES FOR THE PREPARATION OF BOSENTAN AND ITS INTERMEDIATES THEREOF | PTGIS, EDNRB, CYP11B2 | EDNRA 6/4885EDNRB 2/4885ABCC3 2547/4885 |
| US-20030087920-A1 | Butyne diol derivatives | BDKRB2, EDNRB, EDNRA | EDNRA 3/4885EDNRB 2/4885ABCC3 1351/4885 |
| US-20120136015-A1 | PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN) | EDNRA, EDNRB, TBXA2R | EDNRA 1/4885EDNRB 2/4885ABCC3 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.